Risks and limits of FTO Basis

The FTO gene test (e.g., rs1800206) is a classic GWAS-based risk marker. Studies show a statistical link between certain FTO variants and higher BMI, but the effect size is small – typically 1–3 kg difference in body weight. The test is not diagnostic and does not predict individual metabolism. Key risks include overinterpretation: consumers may wrongly believe their weight is genetically predetermined and lifestyle changes are futile. In reality, diet and exercise effects are not negated by genetics. Additionally, most GWAS were conducted in European populations, limiting transferability to other ethnicities. Another limit: the test provides no actionable advice – no personalized diet or exercise prescription. MyBody-X and similar companies market such tests as a 'basis' for health optimization, but evidence for real-world benefit is lacking. Anyone seeking to improve their health should focus on proven lifestyle interventions rather than a single gene variant. Conclusion: The FTO test is scientifically valid but clinically irrelevant – it belongs to the category of informative, not medical, tests.